ABCL vs PTGX
AbCellera Biologics Inc. vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
64
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
64
Buy
| Metric | ABCL | PTGX |
|---|
| AI Score |
64
|
64
|
| Price |
$10.35
|
$151.99
|
| P/E Ratio |
-18.07×
|
121.74×
|
| ROE |
-15.1%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
99.9%
|
| Debt / Equity |
0.15×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
68.1
|
| Beta |
1.191
|
1.794
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus PTGX.
The committee scores are tied.
ABCL and PTGX both score 64/100.
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical